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To the editor:
Keränen and colleagues have investigated the retention rate on
pramipexole (PRX) among patients diagnosed with idiopathic
Parkinson’s disease (PD) in a University Hospital in Finland.
Moreover, they investigated reasons for PRX discontinuation,
and they tried to identify determinants for PRX discontinua-
tion. We welcome their study as a first initiative to identify
reasons for discontinuation and possible determinants.
The authors pointed out that they found a retention rate of
PRX in PD patients that was higher (63% at 3 years) than we
found in our cohort (40% at 3 years) [1], despite similarities in
patient characteristics. We agree that differences in study
methods may have contributed to variation in findings. In our
study, we assessed the (dis)continuation of PRX treatment
with prescription data from pharmacies whereas Keränen et
al. used records of physicians. In our opinion, several factors
have to be taken into account. Firstly, it is possible that not all
changes in medication (discontinuation, dose changes) are
written down in medical records. Therefore, some patients
that have discontinued could be missed. Secondly, there
remains a possibility that some patients have discontinued
their medication without informing their physician. There is
evidence for non-adherence in patients with PD measured
with a computerised monitoring system [2]. However, studies
investigating whether patients actually get their medication
from the pharmacy are lacking. Lastly, the number of visits to
the treating physician (in the study of Keränen et al.) or to the
pharmacy (in our study) could be a factor in the precision of
the estimation of discontinuation. The mean length of PRX
prescriptions in our study was 47 days. This implies that we
had an evaluation moment (use or no use) every 47 days. We
do not know the frequency of visits to the treating physician
in the study of Keränen et al.
Keränen et al. found two non-genetic factors that were
associated with PRX discontinuation: orthostatic hypoten-
sion and entacapone treatment prior to PRX treatment.
These findings are an interesting supplement to our study.
We think, however, that genetic factors should also be
studied in the future [3].
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